More evidence has demonstrated that high mutation load (non-synonymous variation) in tumors were associated with increasing infiltration of CD8+ T cells, which showed that the tumor load mutation (TMB) may play an important role in the immunotherapy response. The gene discussed is CD8A; the disease is neoplasm.